Cargando…
Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?
PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PA...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792109/ https://www.ncbi.nlm.nih.gov/pubmed/36578526 http://dx.doi.org/10.2147/JHC.S388965 |
_version_ | 1784859562909630464 |
---|---|
author | Luo, Laihui He, Yongzhu Zhu, Guoqing Xiao, Yongqiang Song, Shengjiang Ge, Xian Wang, Tao Xie, Jin Deng, Wei Hu, Zhigao Shan, Renfeng |
author_facet | Luo, Laihui He, Yongzhu Zhu, Guoqing Xiao, Yongqiang Song, Shengjiang Ge, Xian Wang, Tao Xie, Jin Deng, Wei Hu, Zhigao Shan, Renfeng |
author_sort | Luo, Laihui |
collection | PubMed |
description | PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PATIENTS AND METHODS: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching. RESULTS: The median duration of conversion therapy was 108 (42–298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL, p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days, p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths. CONCLUSION: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy. |
format | Online Article Text |
id | pubmed-9792109 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-97921092022-12-27 Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? Luo, Laihui He, Yongzhu Zhu, Guoqing Xiao, Yongqiang Song, Shengjiang Ge, Xian Wang, Tao Xie, Jin Deng, Wei Hu, Zhigao Shan, Renfeng J Hepatocell Carcinoma Original Research PURPOSE: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy. PATIENTS AND METHODS: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching. RESULTS: The median duration of conversion therapy was 108 (42–298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL, p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days, p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths. CONCLUSION: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy. Dove 2022-12-22 /pmc/articles/PMC9792109/ /pubmed/36578526 http://dx.doi.org/10.2147/JHC.S388965 Text en © 2022 Luo et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Luo, Laihui He, Yongzhu Zhu, Guoqing Xiao, Yongqiang Song, Shengjiang Ge, Xian Wang, Tao Xie, Jin Deng, Wei Hu, Zhigao Shan, Renfeng Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title | Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title_full | Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title_fullStr | Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title_full_unstemmed | Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title_short | Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference? |
title_sort | hepatectomy after conversion therapy for initially unresectable hcc: what is the difference? |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792109/ https://www.ncbi.nlm.nih.gov/pubmed/36578526 http://dx.doi.org/10.2147/JHC.S388965 |
work_keys_str_mv | AT luolaihui hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT heyongzhu hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT zhuguoqing hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT xiaoyongqiang hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT songshengjiang hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT gexian hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT wangtao hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT xiejin hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT dengwei hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT huzhigao hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference AT shanrenfeng hepatectomyafterconversiontherapyforinitiallyunresectablehccwhatisthedifference |